Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815229 | 0.94 | UBE2M (0.48) | SIGMAR1KDM4EALDH1A1HTR1AHTR7 | |
| SCHEMBL14815277 | 0.94 | UBE2M (0.48) | SIGMAR1HTR1AHTR7CHRM3LMNA | |
| SCHEMBL14815334 | 0.91 | KCNH2 (0.43) | SIGMAR1HTR1AHTR7LMNAKCNH2 | |
| SCHEMBL14815237 | 0.84 | DRD2 (0.43) | KDM4EALDH1A1GAAHTR1AHTR7 | |
| SCHEMBL14815148 | 0.80 | DRD2 (0.48) | KDM4EALDH1A1GAAHTR1AHTR7 | |
| SCHEMBL14815064 | 0.80 | HRH1 (0.45) | ALDH1A1GAACACNA1B | |
| SCHEMBL14815248 | 0.77 | CACNA1B (0.49) | ALDH1A1CACNA1B | |
| SCHEMBL14815482 | 0.76 | HSD11B1 (0.51) | ALDH1A1CACNA1B | |
| SCHEMBL14815352 | 0.76 | CA1 (0.45) | HTR1AHTR7LMNA | |
| SCHEMBL14833227 | 0.73 | DRD2 (0.45) | SIGMAR1KDM4EALDH1A1GAAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | SIGMAR1 410/4885KDM4E 3058/4885ALDH1A1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.